What this is
- Ficus deltoidea shows potential to improve symptoms of () in female rats.
- was induced using letrozole, and the effects of F. deltoidea were assessed on biochemical, hormonal, and histomorphometric parameters.
- Results indicate that F. deltoidea can normalize insulin sensitivity, hormonal levels, and ovarian histology.
Essence
- Ficus deltoidea treatment in letrozole-induced rats improved insulin sensitivity and normalized hormonal levels, suggesting its therapeutic potential for .
Key takeaways
- Ficus deltoidea at doses of 500 and 1000 mg/kg/day significantly reduced and improved hormonal profiles in rats.
- Histomorphometric analysis showed increased corpus luteum numbers and endometrial thickness, indicating improved ovarian function.
- Treatment also restored lipid profiles, with reductions in total cholesterol, triglycerides, and LDL, while increasing HDL levels.
Caveats
- The study is limited to an animal model, and results may not directly translate to humans.
- Further studies are needed to explore the long-term effects and mechanisms of F. deltoidea in treatment.
Definitions
- Polycystic ovarian syndrome (PCOS): A hormonal disorder causing enlarged ovaries with small cysts, affecting women's reproductive health.
- Insulin resistance: A condition where cells in the body become less responsive to insulin, leading to elevated blood sugar levels.
AI simplified
Background
Polycystic ovarian syndrome (PCOS) is a chronic endocrine disorder that occurs in women of reproductive age. It is estimated to affect up to 4–12% of women worldwide [1]. PCOS often develops due to an imbalance of reproductive hormones and insulin resistance. The major clinical features of PCOS include ovarian cysts, irregular menstrual cycles, weight gain, and fertility problems [2]. The formation of ovarian cysts can interrupt ovulation and eventually leads to infertility. It is therefore not surprising that the prevalence of infertility in women with PCOS is about 70 to 80% [3]. PCOS has also been found to increase the risk of miscarriage, anxiety, and depression [4].
Metformin and clomiphene citrate are the common drugs prescribed for women with PCOS [5]. Treatment with metformin and clomiphene citrate improved ovulation and pregnancy rates of infertile patients with PCOS [6]. However, these treatments are significantly less effective in obese women with PCOS. It is important to note that about 40–60% of women with PCOS are overweight or obese [7]. Metformin and clomiphene citrate treatment are also associated with several adverse effects such as diarrhea, nausea, vaginal/uterine bleeding, breast tenderness, hot flashes, and abdominal pain [8].
Plants have been used for decades to address human fertility issues, and one of them is Ficus deltoidea or also known as Mas Cotek in Malaysia. F. deltoidea is growing wild in Kelantan, Terengganu, Sabah, Sarawak, and Kalimantan. It has recently been formulated, packaged, and distributed as a tonic tea, tea, and capsules across countries, in addition to being boiled in water for consumption [9]. The methanolic extract of F. deltoidea leaf has been reported to be rich in tannins, alkaloids, saponins, phenols, flavones, isoflavones, and flavonoids [10]. The presence of these compounds is beneficial for treating dyslipidemia, diabetes, heart disease, cancer, and infertility cases such as PCOS [11]. The antihypertensive [12], chemopreventive, and chemotherapeutic [13] activities of F. deltoidea have indeed been reported in animal studies. F. deltoidea also improved depressive behavior in rats [14]. Our previous studies have demonstrated that F. deltoidea is not only capable of promoting fertility in diabetic male rats [15] but also improving hormonal balance in PCOS female rats [16]. We have also shown that F. deltoidea increased cognitive performance [17] and attenuated tissue morphology changes by increasing antioxidant activities in diabetic rats [18, 19]. To the best of our knowledge, despite past extensive studies, the therapeutic activity of F. deltoidea on PCOS rats has not yet been fully elucidated. We presently examine the effects of F. deltoidea on the hormonal profile, biochemical parameters, and histological changes in LTZ-induced PCOS in rats to address these gaps in knowledge.
Methods
Sample collection and identification
F. deltoidea leaves were purchased from Moro Seri Utama Enterprise, Batu Pahat, Johor, Malaysia in September 2016. Following taxonomic authentication, the leaves sample was deposited at the Herbarium Unit, Universiti Kebangsaan Malaysia, Bangi with a voucher specimen (UKMB40315).
Preparation ofmethanolic extract F. deltoidea
The leaves of F. deltoidea were cleaned with running tap water and air-dried in an air oven at 40 °C. The dried leaves were then ground to obtain a fine brownish powder [20]. For extraction, the powder was macerated with 1 L of absolute methanol (95%) for three days at 27 °C with a ratio of 1:10 [21]. The liquid extract was evaporated under reduced pressure at 40 °C using a rotary evaporator (Buchi, Switzerland). The dried extract was divided into smaller batches in tightly closed glass jar and stored at − 20 °C until further use to reduce moisture and contamination.
Selection of doses ofextract F. deltoidea
The decoction of F. deltoidea is commonly taken twice daily by an adult human, 80–100 mL each time. This volume intake represents about 25–40 g of the extract per day as the yield of the hot water extract of F. deltoidea approximately 18% [19]. The dose for the rat was then calculated using the conversion of human equivalent dose (HED) to animal equivalent dose (AED) equation (conversion factor 0.018) based on body surface area [22] as stated below:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\mathrm{AED}\ \left(\mathrm{mg}/\mathrm{kg}\right)=\mathrm{HED}\ \left(\mathrm{mg}/\mathrm{kg}\right)\ \mathrm{X}\ \mathrm{conversion}\ \mathrm{factor}$$\end{document}AEDmg/kg=HEDmg/kgXconversionfactor
Based on this calculation, the possible effective dose of F. deltoidea for a rat is ranging between 450 and 720 mg/kg. A toxicity study done by Farsi et al. [21] demonstrated that the LD50 of the metabolic extract of F. deltoidea was greater than 5000 mg/kg. Considering these factors, three doses were selected to access the effectiveness of F. deltoidea to alleviate PCOS symptoms. The three-dose levels are 250 mg/kg (1/20 of LD50), 500 (1/10 of LD50), 1000 mg/kg (1/5 LD50).
Animals
Female Sprague-Dawley rats (8 weeks old, N = 36) weighing between 140 and 170 g were procured from Chenur Sdn. Bhd. Serdang, Selangor. Animals were caged in temperature-controlled steel cages (20–22 °C, 55–65% humidity) with a 12-h light/dark cycle and were feed standard rat chow (Gold Coin Holdings, Kuala Lumpur, Malaysia) and water ad libitum. Rats were allowed to acclimatise for ten days before the experiments. Daily vaginal smears were performed on all rats to evaluate the ovarian function as described by Karateke et al. [23]. Changes in ovulation phases were determined by the number of cornified cells, nucleated epithelial cell leukocytes in vaginal smear morphology. The procedures were performed at 09:00–10:00 AM daily to avoid hormonal fluctuations that may interrupt the cycles. Only those experimental rats displaying two consecutive regular 4-day cycles were included in the study.
Induction of PCOS rat model
Animals were induced to develop PCOS with LTZ at 1 mg/kg b.wt dissolved in 2 mL/kg/day of saline for 21 days [24]. Approximately 0.5 mL of blood samples were collected before and after PCOS induction from the jugular vein. The samples were centrifuged to obtain serum for testosterone level analysis. Female rats that showed significantly higher levels of testosterone than normal rats with the absence estrus phase in their estrous cycle were selected to represent the PCOS model in this study [25].
Experiment design
Thirty-six adult female Sprague Dawley rats were randomly assigned into six groups with six rats per each as follows: (i) normal control (NC) received saline at 2 mL/kg/day, (ii) PCOS control (PC) received saline at 2 mL/kg/day, (iii) PCOS rats treated with clomiphene citrate-treated group at 10 mg/kg/day (PCC), (iv) PCOS rats treated with F. deltoidea at 250 mg/kg/day group (PFD250), (v) PCOS rats treated with F. deltoidea at 500 mg/kg/day group (PFD500), and (vi) PCOS rats treated with F. deltoidea at 1000 mg/kg/day group (PFD1000).
Clomiphene citrate (Sigma Chemical Co.) and F. deltoidea extract were suspended in 2 mL saline. All treatment was administered via oral gavage for 15 consecutive days [26]. Daily vaginal smears were continuously performed to determine the changes in estrous cycles (absence of estrus stage). All rats were sacrificed at the onset of the diestrus phase [27] as the morphology of female reproductive organs is greatly influenced by the stage of estrous cycles [28].
At the end of the experiment, animals were allowed to fast for 12 h. Fasting blood glucose was determined using Accu-check Advantage II Blood Glucose Monitor (Roche Mannheim, Germany, the upper limit of detection 33.3 mM). Rats were anesthetized with diethyl ether (1.9%) in a large desiccator. The blood was collected from the abdominal aorta into a plain EDTA red-top tube (BD Vacutainer, USA). Serum was kept at − 80 °C for biochemical analysis and hormonal profile. The rats were sacrificed by cutting off the diaphragm. Ovary and uterus were identified, dissected out from the surrounding fats, and measured (weight for ovaries and uteri; length for uteri). The separation of the horns of the uterus from the vagina was done by cutting the uppermost point of the cervix. The right ovary and uterus of each rat were used for antioxidant assay while the left side of these organs was preserved in 10% formalin for histomorphometric analysis.
Physical parameters measurement
Pre and post body weight and length of the rats were measured at approximately 16:00 clocks during the experiment. Body mass index (BMI), and Lee index were calculated to estimate obesity in animals. The BMI was calculated by dividing the weight (g) by the length (cm2) [29]. Body length was defined as the distance from the nose to the anus of rats. Meanwhile, Lee index for each animal was measured by dividing the cube root of the body weight (g) by the naso-anal length (cm2) and multiplying the whole expression by 10,000. Rats were considered obese if Lee index value is higher than 310 [30].
Determination of insulin resistance
Serum insulin concentrations were quantified by Ultra-Sensitive Rat Insulin ELISA kit (Cloud-Clone Corp., Houston, USA) as described by Nurdiana et al. [17]. Homeostatic Model Assessment Insulin resistance (HOMA-IR) was calculated according to Shen et al. [31] as follows:\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\mathrm{HOMA}-\mathrm{IR}=\frac{\mathrm{Fasting}\ \mathrm{Blood}\ \mathrm{Glucose}\ \left(\mathrm{FBG}\right)\ \mathrm{x}\ \mathrm{Fasting}\ \mathrm{Insulin}\ \left(\mathrm{FINS}\right)}{405}$$\end{document}HOMA-IR=FastingBloodGlucoseFBGxFastingInsulinFINS405
Analysis of gonadotropins and steroids hormones
The levels of serum testosterone (T), estrogen (E), progesterone (P), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were measured using Rats ELISA kits procured from Qayee Biotechnology Co., LTD, Shanghai, China. Each hormone was analysed using different kits according to specific antibodies, Horseradish Peroxidase, and the manufacturer’s instructions.
In brief, 10 μL of the serum samples were added (Insulin: 10 μL, Progesterone: 10 μL, Testosterone: 10 μL, Estrogen: 10 μL) into respective pre-coated ELISA plates. The plates were incubated for 1 h. After incubation, the plates were washed five times with 350 μL of diluted washing liquid for 2 min. 50 μL of each chromogen A and chromogen B was further added into each well, gently shaken, and incubated for 10 min. at 37 °C in a dark room as the chromogen is very sensitive to light and may cause sample contamination. Then, 50 μL of Stop solution was added to each well to stop the reaction indicated by a change of colour from blue to yellow. The optical density (OD) was then read at 450 nm wavelength within 15 min. After the stop solution was added. A standard curve was constructed by plotting a graph of the absorbance of each reference standard against its corresponding levels and used to determine each of the hormone levels.
Measurement of serum lipid
The levels of total cholesterols (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL), and high-density lipoprotein cholesterol (HDL) were determined using an automatic analyser (Hitachi 911, Boehringer-Mannheim, Germany).
Measurement of antioxidant and oxidative stress biomarkers
Serum samples were used to assay the activities of antioxidant enzymes, MDA concentrations, and total protein. Bradford method was used to assess the protein concentration in supernatants, with bovine serum albumin as the reference (Sigma Aldrich, St. Louis, MO, USA, Cat. No. B6916).
Histology analysis
The histological procedures involved in this study were conducted according to the methods mentioned by Mvondo et al. [32]. Ovary and uterus of rats were immersed and fixed in formalin (10%) solution for at least 48 h at room temperature. The selected organs were embedded in paraffin wax, sectioned at 5-μm using Leica RM2245 microtome (Leica Biosystems, Wetzlar, Germany), and air-dried in a vertical position. Ten serial sections of each sample were collected for H&E staining. Histomorphological changes were assessed on microphotographs using a DP70 digital light microscope system (Olympus, Tokyo, Japan) equipped with a camera. The captured image was transferred and analysed with the ImageJ software. Corpus luteum was identified as large, round or irregular glandular structures composed of multiple layers of large granulosa lutein cells. Ovarian cysts were identified as cyst-like structures within the ovary lined by a thin layer of degenerating granulosa cells. Follicles containing an oocyte with a nucleus were counted and described as healthy [23].
Statistical analysis
All data were expressed as mean ± standard error of the mean (SEM), except data of the estrous cycle. All measurements were assessed for normality using the Kolmogorov-Smirnov test. The unpaired Student t-test was used to compare the initial and final physical parameters. One-way analysis of variance (ANOVA) followed by Duncan multiple comparison post hoc tests was performed to elucidate the statistical differences between the experimental groups. Differences were considered significant at p < 0.05.
Results
Physical parameters
| Groups | InitialBody weight (g) | FinalBody weight (g) | InitialBMI (g/cm)2 | FinalBMI(g/cm)2 | InitialLee’s Index | FinalLee’s Index |
|---|---|---|---|---|---|---|
| NC | 200.01±5.38a | 218.66±5.27a | 0.48±0.01a | 0.47±0.01a | 283.15±3.97a | 281.52±2.21a |
| PC | 268.25±9.67b,x | 298.28±7.33c,y | 0.57±0.02b | 0.59±0.02c | 317.1±3.95b | 311.43±6.31c |
| PCC | 261.35±5.39b, | 272.15±5.81b | 0.57±0.03b | 0.55±0.02b,c | 299.83±1.93b | 301.35±3.54a,b |
| PFD250 | 260.85±3.47b, | 268.97±6.57b, | 0.56±0.01b | 0.55±0.03b,c | 297.27±2.28b | 297.99±5.94b |
| PFD500 | 260.44±2.04b | 270.78±5.53b | 0.58±0.02b,x | 0.52±0.02a,b,y | 303.85±5.17b,x | 284.58±3.89a,b,y |
| PFD1000 | 267.42±6.62b | 268.42±4.67b | 0.57±0.03b,x | 0.51±0.02a,b,y | 298.03±4.49b,x | 278.73±3.40a,y |
Estrous cycle
Phases of the estrous cycle in female rats at different days of treatment. NC: normal control; PC: letrozole-induced PCOS control; PCC: clomiphene citrate; PFD250: 250 mg/kg/day of; PFD500: 500 mg/kg/day ofand PFD1000: 1000 mg/kg/day of. Data show the most represented phase of the estrous cycle in each group,= 6. P = proestrous, E = estrous, M = metestrus, and D = diestrous F. deltoidea F. deltoidea, F. deltoidea n
HOMA-IR analysis
| Parameters | Experimental group | |||||
|---|---|---|---|---|---|---|
| NC | PC | PCC | PFD250 | PFD500 | PFD1000 | |
| FBG (mg/dL) | 103.42±1.22a | 122.82±6.21c | 109.01±3.25a | 118.92±2.85b,c | 115.06±1.49b,c | 114.41±2.82a,b |
| FINS (μU/mL) | 1.49±0.10a | 2.69±0.12b | 1.68±0.18a | 1.84±0.14a | 1.75±0.09a | 1.65±0.12a |
| HOMA-IR | 1.46±0.04a | 2.09±0.21c | 1.64±0.10a,b | 1.94±0.09b,c | 1.78±0.04a,b | 1.79±0.09a,b |
Hormonal profiles
| Hormones | Experimental group | |||||
|---|---|---|---|---|---|---|
| NC | PC | PCC | PFD250 | PFD500 | PFD1000 | |
| Testosterone (ng/mL) | 93.45±2.26a | 119.11±4.86c | 93.15±4.50a | 110.98±4.57b,c | 98.64±4.28a,b | 94.19±3.03a |
| Estrogen (pg/mL) | 60.9±2.33b | 40.94±7.59a | 65.37±3.43b | 53.46±6.11a,b | 60.19±5.70b | 64.69±4.74b |
| Progesterone (ng/mL) | 12.49±0.97c | 8.55±0.89a | 10.13±0.50b,c | 9.23±0.99a,b | 10.06±0.47b,c | 12.15±0.81c |
| FSH (mIU/mL) | 12.52±0.91a | 18.99±0.59b | 13.88±0.80a | 14.29±1.14a | 13.9±1.37a | 13.14±0.74a |
| LH (ng/mL) | 24.06±1.16a | 38.82±4.56c | 30.46±1.56a,b | 37.73±0.85c | 33.48±1.90b,c | 29.45±1.20a,b |
Serum lipid profile
| Lipids Parameters | Groups | |||||
|---|---|---|---|---|---|---|
| NC | PC | PCC | PFD250 | PFD500 | PFD1000 | |
| Total cholesterol (mmol/L) | 1.872±0.11b,c | 2.603±0.10d | 1.233± 0.10a | 2.052± 0.06c | 1.85±0.10b,c | 1.742±0.10b |
| Triglycerides (mmol/L) | 0.644± 0.05a | 1.462± 0.12c | 0.603± 0.98a | 1.072± 0.11b | 0.962±0.05b | 0.665±0.07a |
| LDL-C (mmol/L) | 0.288± 0.09b | 0.435± 0.02d | 0.2± 0.17a | 0.413± 0.02d | 0.378±0.03c,d | 0.335±0.02b,c |
| HDL-C (mmol/L) | 1.572± 0.09b | 1.227± 0.07a | 1.547± 0.06b | 1.553± 0.08b | 1.588±0.08b | 1.55±0.08b |
Antioxidant and oxidative stress activities
| Groups | Antioxidant enzymes and lipid peroxidation levels | ||
|---|---|---|---|
| SOD (U/mL) | GSH-Px (U/L) | TBARS (μmol, MDA) | |
| NC | 1.90 ± 0.15b | 65.47 ± 1.622d | 1.69 ± 0.14a |
| PC | 0.78 ± 0.09a | 40.44 ± 3.52a | 4.03 ± 0.34c |
| PCC | 1.66 ± 0.27b | 52.61 ± 3.68b,c | 2.22 ± 0.37a |
| PFD250 | 0.85 ± 0.17a | 43.02 ± 3.31a,b | 3.43 ± 0.34b,c |
| PFD500 | 1.37 ± 0.24a,b | 48.58 ± 2.74a,b,c | 2.72 ± 0.39a,b |
| PFD1000 | 1.70 ± 0.29b | 55.27 ± 5.46c,d | 2.09 ± 0.29a |
Ovarian Histomorphometric changes
Photomicrographs of the representative ovarian cross-section at different magnification from all experimental groups. NC group displaying normal histological appearance with corpus luteum (CL) and several healthy follicles (HF). Ovarian cross-sections from the PC group showing many cystic follicles (*) with lesser CL and HF. PCC group showing reduced cystic follicles (*) with abundant CL and HF. PFD250 group was associated with fewer cystic follicles (*) and the presence of HF and CL. PFD500 and PFD1000 groups showing vast improvement in the histological structure by the absence of cystic follicles (*) and many HF and CL which were almost comparable with the NC group. The cross-sections were stained with heamatoxylin-eosin (H&E) with 4X and 40X magnification. NC: normal control; PC: letrozole-induced PCOS control; PCC: clomiphene citrate; PFD250: 250 mg/kg/day of; PFD500: 500 mg/kg/day ofand PFD1000: 1000 mg/kg/day of F. deltoidea F. deltoidea, F. deltoidea
| Groups | Ovary weight (g) | Total numbers of cystic follicles | Numbers of corpus luteum | Numbers of healthy follicles |
|---|---|---|---|---|
| NC | 0.20 ± 0.02b | 1.20 ± 0.20a | 5.40 ± 0.51c,d | 10.40 ± 0.50c |
| PC | 0.11 ± 0.01a | 8.50 ± 0.43e | 2.33 ± 0.33a | 4.17 ± 0.48a |
| PCC | 0.17 ± 0.02b | 2.17 ± 0.31a,b | 6.07 ± 0.37d | 9.50 ± 0.62c |
| PFD250 | 0.20 ± 0.02b | 7.00 ± 0.36d | 3.17 ± 0.40a,b | 4.33 ± 0.42a |
| PFD500 | 0.20 ± 0.01b | 2.83 ± 0.47b | 4.16 ± 0.60b,c | 6.33 ± 0.42b |
| PFD1000 | 0.22 ± 0.03b | 4.20 ± 0.37c | 4.20 ± 0.37b,c | 7.20 ± 0.58b |
Uterine Histomorphometric changes
Photomicrographs of the representative uterine cross-section at different magnification from all experimental groups. NC group showing normal histological appearance with normal endometrium wall (red arrow), and endometrial gland (EG) (black arrow). PC group displaying a thin endometrium wall with lesser EG. PCC group showing visible endometrium wall with abundant EG. PFD250 group showing less visible endometrium wall with several. PFD500 and PFD1000 displaying an improvement in the histological structures by the presence of EG, visible endometrium wall, and thick uterus which were almost comparable with the NC group. The cross-sections were stained with heamatoxylin-eosin (H&E) with 4X and 40X magnification. NC: normal control; PC: letrozole-induced PCOS control; PCC: clomiphene citrate; PFD250: 250 mg/kg/day of; PFD500: 500 mg/kg/day ofand PFD1000: 1000 mg/kg/day of F. deltoidea F. deltoidea, F. deltoidea
| Group | Uterine weight (g) | Uterus Length (μm) | Endometrium Thickness (μm) | Numbers of Endometrial gland (n) |
|---|---|---|---|---|
| NC | 0.46 ± 0.03b,c | 183.05 ± 3.07c,d | 135.79 ± 2.91c | 11.80 ± 0.66b |
| PC | 0.28 ± 0.02a | 135.67 ± 2.79a | 86.71 ± 1.43a | 6.17 ± 0.31a |
| PCC | 0.44 ± 0.06b,c | 200.00 ± 2.79d,e | 133.07 ± 2.58b,c | 12.00 ± 0.58b |
| PFD250 | 0.35 ± 0.02a,b | 158.72 ± 3.33b | 115.37 ± 8.13b | 6.67 ± 0.66a |
| PFD500 | 0.37 ± 0.05a,b,c | 172.25 ± 2.98b,c | 123.85 ± 4.91b,c | 12.50 ± 0.56b |
| PFD1000 | 0.49 ± 0.06c | 210.95 ± 19.75e | 139.80 ± 11.51c | 14.40 ± 0.68c |
Discussion
The present study demonstrated that LTZ-induced PCOS rats exhibit the clinical and biochemical characterizations of women with PCOS. In line with previous observations, our results showed PCOS-like conditions in rats including an abnormal estrus cyclicity, elevated body weight, insulin resistance, total cholesterol, triglycerides, LDL-C, MDA, LH, FSH, and testosterone levels [33]. The animals also had lower HDL-C, estrogen, progesterone, SOD, and GSH-Px levels than the normal control group. We demonstrated, for the first time, that treatment with F. deltoidea at 500 and 1000 mg/kg/day can ameliorate PCOS symptoms in rats by improving insulin resistance, antioxidant activity, and hormonal balance. We also showed that F. deltoidea significantly decreases the number of cystic follicles, increases the number of corpus luteum, and normalizes the endometrium thickness.
Treatment with LTZ to adult rats for 21 days increased body weight, BMI, Lee’s index (Table 1), and resulted in disruption of the estrous cycle (Fig. 1). Lee’s index values of the PC group were higher than 310 throughout the experimental period, indicating the efficacy of LTZ in the induction of PCOS. A significant increase between the initial and final measurement of BMI further confirms the overweight and obesity incidence in PCOS rats. Similar findings have been reported in different animal models of PCOS [34–36]. It is important to note that F. deltoidea treatment at 500 and 1000 mg/kg/day for up to 15 days significantly reduced BMI and Lee’s Index values in PCOS rats. A small weight loss of approximately 5% can improve insulin resistance, hormone levels, menstrual cycles, and infertility associated with PCOS [37, 38]. Indeed, lower HOMA-IR values were found in the PFD500 and PFD1000 groups (Table 2), suggesting the insulin-sensitizing activity of F. deltoidea. Animals in these groups were also associated with improvement in estrous cyclicity during the treatment phase. These findings were consistent with the notion that insulin sensitiser may improve menstrual cyclicity and ovulation in PCOS [39].
We demonstrated that F. deltoidea treatment at 500 and 1000 mg/kg/day significantly reduced the concentrations of testosterone, FSH, and LH as well as increased estrogen and progesterone to near-normal levels in PCOS rats (Table 4). These results imply that F. deltoidea exhibited anti-androgenic and estrogenic properties in PCOS rats that in turn can explain the suppression of FSH and LH. A similar finding has been reported by Nur Ajeerah et al. [16]. Supporting this view, the presence of catechin, gallocatechin, and epigallocatechin have been reported by Haida et al. [40]. Catechin is known to suppress appetite, reduce food consumption, and is responsible for the reduction in testosterone level [41, 42]. Meanwhile, epigallocatechin and apigenin were proven to inhibit 17β-HSD, 3β-HSD enzymes, and P450 activity that lead to inhibitory effects on testosterone production. However, Rocha et al. [43] demonstrated that normalization of testosterone levels did not improve BMI, glucose, or lipid metabolism in postmenopausal hyperandrogenism rats. It should be mentioned that the effects of serum androgen normalization are different in reproductive and non-reproductive status. It has also been shown that therapy aimed at reducing androgen over-production failed to ameliorate insulin resistance in PCOS [44]. Further analyses are, therefore, needed to assess the biological outcomes following F. deltoidea.
Lipid disturbances are the most common metabolic abnormality in PCOS. Our current results showed that the administration of LTZ for 21 days was not only able to develop PCOS symptoms similar to those occurring in humans but also affect the serum lipid profiles (Table 4). A similar finding has been reported by Ndeingang et al. [45]. Nevertheless, Wasan et al. [46] provide evidence that LTZ did not significantly alter serum lipid profile. This discrepancy can be justified by the fact that LTZ only has a good short-term tolerability profile [47]. Continuous exposure to LTZ has been demonstrated to cause significant changes in lipid profile [48]. It was found that F. deltoidea restored the levels of total cholesterol, triglycerides, LDL-C, and HDL-C to normal levels in PCOS rats that had improvement in hormonal profile and the estrous cycle. The data support that the relationship between lipid profile and sex hormones [49, 50]. These results are also compatible with earlier studies demonstrating that F. deltoidea can reverse the abnormalities in the lipid profile of diabetic rats [51] and adults with pre-diabetes [52],
Lipid peroxidation and antioxidants were further evaluated to understand the potential of F. deltoidea in treating PCOS. We found that the PCOS rats had higher serum MDA and lower endogenous antioxidant enzymes (SOD and GSH-Px) levels than normal control (Table 5), indicating oxidant-antioxidant imbalance occurred. A disturbance in the antioxidant-prooxidant balance has been reported to induce pathological consequences in oocyte maturation, ovulation, fertilization, implantation, and embryo development [53]. In contrast, PCOS animals in the PFD500 and PFD1000 groups had a significantly lower level of MDA but higher SOD and GSH-Px activities. These findings in agreement with data which were reported the prospect of oxidative stress modulator-natural antioxidants as therapeutic interventions for managing PCOS [54]. However, an increase in SOD activity has also been reported in women with PCOS [55]. A higher level of SOD activity and reduced levels of glutathione peroxidase has been shown to disrupt the efficiency of ROS scavenging in the follicular environment [56]. Therefore, histomorphometric analysis of the ovary and uterine tissues are required to confirm these results.
PCOS has been demonstrated to induce histo-architectural changes in the ovary [57] and uterus [58] of rats. In agreement with previous studies on PCOS animal models, fewer numbers of corpus luteum and multiple follicular ovarian cysts were observed in the PC group [59, 60]. Reduction in ovarian weight, uterine length and weight, endometrium thickness, and numbers of the endometrial gland are consistent with decreasing levels of testosterone, FSH, LH, and antioxidants activities. Our study provides additional support for the association between reproductive hormone levels and gonadal morphology in rats with PCOS. Importantly, significant increases in the numbers of corpora lutea, ovarian and uterine weight, endometrium thickness, and numbers of the endometrial gland, together with a decrease in the numbers of cystic follicles were found in the PCC, PFD500, and PFD1000 groups. The appearance of corpora lutea suggest that these animals have ovulated. Higher levels of progesterone obtained in these groups confirmed that ovulation has occurred. It is important to note that the management of PCOS is aimed mainly at restoring ovulation.
Taken together, our results showed that F. deltoidea extract effectively ameliorates biochemical, hormonal, and histomorphometric changes to levels comparable with those reported in the clomiphene citrate-treated rats. It may be suggested that F. deltoidea extract promotes adiponectin, a protein hormone that modulates several metabolic processes, including glucose regulation and fatty acid oxidation [61]. These results support the hypothesis that a combination of lipid-lowering with insulin-sensitizing agents would achieve better therapeutic effects in the treatment of PCOS [62]. Therefore, future studies are required to determine the value of serum adiponectin levels in the PCOS rat model.
Conclusion
We conclude that F. deltoidea can reverse the symptoms of PCOS in female rats by improving insulin sensitivity, lipid profile, antioxidant activity, hormonal balance. These findings improve our current understanding of the potential use of F. deltoidea for the treatment of PCOS.